Carvedilol Tablet, Film Coated
Product Images NDC 0904-7305

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 0904-7305). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Figure 1)

A line graph comparing percent mortality over 21 months between Carvedilol and placebo groups. The y-axis shows % mortality, and the x-axis shows time in months. The graph indicates lower mortality in the Carvedilol group compared to placebo, with a p-value of 0.0014 shown.*

FDA Label Image

Figure-2 (Figure 2)

A forest plot displaying hazard ratios with confidence intervals across various patient subgroups including sex (men, women), age (<65, ≥65), race (non-black, black), diabetic status, ischemic status, heart rate, systolic blood pressure, and spironolactone use. Each subgroup is represented by a dot and horizontal line indicating the hazard ratio and its confidence interval, with the vertical reference line at 1.0.*

FDA Label Image

Figure-3 (Figure 3)

A survival analysis chart for CAPRICORN (intent-to-treat) showing percentage mortality over 24 months. The graph compares mortality rates between Carvedilol and placebo groups, with Carvedilol demonstrating a lower mortality percentage over time. The P-value is noted as 0.03, indicating statistical comparison significance.*

FDA Label Image

Figure-4 (Figure 4)

A forest plot titled 'Figure 4. Effects on Mortality for Subgroups in CAPRICORN' depicting hazard ratios for various patient subgroups. The subgroups include age, gender, timing of randomization post-myocardial infarction, prior use of IV/oral beta blockers, Killip class, thrombolytic therapy, percutaneous transluminal coronary angioplasty (PTCA), presence of congestive heart failure, diuretic use during MI, angina, hypertension, diabetes, heart rate, systolic blood pressure, and an overall patient group. Each subgroup has a plotted hazard ratio with confidence intervals along a horizontal axis ranging from 0.4 to 1.3.*

FDA Label Image

3.125mg Carton Label (Image 01)

Carvedilol 3.125 mg tablets, USP, film-coated, oral dosage form in a unit dose package. The label shows a 100-tablet count, packaged by Major Pharmaceuticals. It includes information on storage instructions, usage directions, and safety warnings. The packaging displays NDC number 0904-7305-61 and states Rx only.*

FDA Label Image

25mg Carton Label (Image 02)

Carvedilol 25 mg tablets, USP, by Major Pharmaceuticals. The label shows unit dose packaging containing 100 tablets (10x10). It includes storage instructions, safety precautions, and usage notes specifying prescription use only and institutional use. The label displays the NDC 0904-7308-61 and the Major Pharmaceuticals contact information in Indianapolis, IN.*

FDA Label Image

Logo (Logo)

FDA Label Image

Logo1 (Logo1)

FDA Label Image

Carvedilol-chemical-structure (Structure)

Chemical structure diagram of Carvedilol, showing its molecular arrangement with labeled atoms and bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.